- Home
- KEP vs GMAB Comparison
KEP vs GMAB Comparison
Compare KEP & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KEP | GMAB |
|---|---|---|
| Founded | 1961 | 1999 |
| Country | South Korea | Denmark |
| Employees | 48650 | 3088 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9B | 16.5B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | KEP | GMAB |
|---|---|---|
| Price | $12.46 | $29.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $39.56 |
| AVG Volume (30 Days) | 1.2M | ★ 2.0M |
| Earning Date | 06-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.18 | $17.85 |
| Revenue Next Year | $2.21 | $16.04 |
| P/E Ratio | $4.54 | ★ $1.90 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.25 | $21.00 |
| 52 Week High | $23.41 | $35.43 |
Technical Indicators
Market Signals| Indicator | KEP | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 55.12 | 62.60 |
| Support Level | $12.34 | $28.01 |
| Resistance Level | $12.85 | $29.62 |
| Average True Range (ATR) | 0.24 | 0.58 |
| MACD | 0.13 | -0.04 |
| Stochastic Oscillator | 95.98 | 85.30 |
Price Performance
Historical ComparisonAbout KEP Korea Electric Power Corporation
Korea Electric Power Corp is an electric utility company in which the government of South Korea holds a controlling stake. The firm operates in the following segments: Transmission and distribution, Electric power generation (Nuclear), Electric power generation (Non-Nuclear), Plant maintenance & engineering service, and Others. The majority of the energy produced by the company comes from its nuclear and coal-fired assets. Korea Electric Power generates revenue through the Transmission and distribution segment. Geographically, it derives maximum revenue from Domestic operations.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.